Trial reportMedicine2025
Oral cryotherapy by Kangfuxin for prophylaxis of oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiation-induced skin injury: a review of pathophysiology, assessment, management, and re-irradiation protocols.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Oral mucositis is a common complication in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT), and currently, there is no universally effective treatment. This study aims to evaluate the preventive and delaying effects of oral cryotherapy using Kangfuxin (KFX) on oral mucositis in auto-HSCT patients. A total of 86 patients, treated between January 2020 and August 2023, were randomly assigned into 2 groups: the control group (40 cases) received cryotherapy using frozen physiological saline ice cubes, and the experimental group (46 cases) received KFX ice cubes. Both treatments started 30 minutes before melphalan infusion, and continued until the end of the infusion. The primary outcome was the incidence and severity of oral mucositis, with secondary outcomes including pain levels and patient-reported general condition. The experimental group demonstrated a significantly higher proportion of patients with grade 0 oral mucositis compared to the control group. Furthermore, the incidence of grade III-IV oral mucositis in the control group was 32.5%, compared to 10.8% in the experimental group, showing a statistically significant difference (P < .05). The experimental group had fewer days of using lidocaine mouthwash and lower pain scores, showing statistically significant differences (P < .05). In conclusion, our findings suggest that KFX oral cryotherapy can be an effective approach for preventing and reducing the severity of oral mucositis in patients undergoing auto-HSCT. It may help alleviates the symptoms such as pain and discomfort, thereby improving patient well-being during treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.